Similar articles

• Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.

  Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R. Imamura T, et al. Circ J. 2013;77(2):397-404. doi: 10.1253/circj.cj-12-0971. Epub 2012 Nov 3. Circ J. 2013. PMID: 23131721 Clinical Trial.
• Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.

  Imamura T, Kinugawa K. Imamura T, et al. Int J Mol Sci. 2016 Jan 14;17(1):105. doi: 10.3390/ijms17010105. Int J Mol Sci. 2016. PMID: 26784173 Free PMC article. Review.
• Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.

  Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Shiga T, Hatano M, Yao A, Kyo S, Komuro I. Imamura T, et al. Circ J. 2013;77(5):1208-13. doi: 10.1253/circj.cj-12-1328. Epub 2013 Jan 12. Circ J. 2013. PMID: 23318562
• Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.

  Toda H, Nakamura K, Nakahama M, Wada T, Watanabe A, Hashimoto K, Terasaka R, Tokioka K, Nishii N, Miyoshi T, Kohno K, Kawai Y, Miyaji K, Koide Y, Tachibana M, Yoshioka R, Ito H; Tolvaptan Registry Investigators. Toda H, et al. J Cardiol. 2016 Feb;67(2):177-83. doi: 10.1016/j.jjcc.2015.04.017. Epub 2015 Jun 10. J Cardiol. 2016. PMID: 26072263
• Tolvaptan for heart failure patients with volume overload.

  Hori M. Hori M. Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S1-4. doi: 10.1007/s10557-011-6298-4. Cardiovasc Drugs Ther. 2011. PMID: 21537921 Review. No abstract available.